Xenetic Biosciences Inc (NASDAQ:XBIO) saw a significant increase in short interest in the month of November. As of November 15th, there was short interest totalling 108,700 shares, an increase of 84.2% from the October 31st total of 59,000 shares. Based on an average daily volume of 633,000 shares, the short-interest ratio is currently 0.2 days. Approximately 2.4% of the company’s shares are sold short.
Separately, ValuEngine raised shares of Xenetic Biosciences from a “hold” rating to a “buy” rating in a research note on Wednesday, October 2nd.
Shares of XBIO stock opened at $1.17 on Wednesday. The company’s fifty day simple moving average is $1.22 and its 200-day simple moving average is $2.53. Xenetic Biosciences has a 52 week low of $0.93 and a 52 week high of $42.84.
Xenetic Biosciences Company Profile
Xenetic Biosciences, Inc is a biopharmaceutical company focused on progressing XCART, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens. The Company is initially advancing cell-based therapeutics targeting the unique B-cell receptor on the surface of an individual patient’s malignant tumor cells for the treatment of B-cell lymphomas.
Featured Article: How is an ETF different from a mutual fund?
Receive News & Ratings for Xenetic Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xenetic Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.